durvalumab + eribulin

Durvalumab + eribulin is a combination therapy being investigated for the treatment of HER2-negative metastatic breast cancer (MBC) and recurrent ovarian cancer (ROC). Durvalumab is a humanized monoclonal antibody that targets the programmed cell death ligand-1 (PD-L1) receptor, while eribulin is a microtubule inhibitor with proven overall survival benefit in metastatic breast cancer. The combination aims to enhance immune responses by leveraging eribulin's ability to release tumor-associated antigens through cytotoxic chemotherapy and its potential to induce intratumoral vascular remodeling, which may improve the efficacy of immune checkpoint blockade with durvalumab.

Brand names

ImfinziHalaven

Other names

Durvalumab and eribulin